RT Journal Article
SR Electronic
T1 Using genome-wide association results to identify drug repurposing candidates
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.06.22279660
DO 10.1101/2022.09.06.22279660
A1 Bell, Nathaniel
A1 Uffelmann, Emil
A1 van Walree, Eva
A1 de Leeuw, Christiaan
A1 Posthuma, Danielle
YR 2022
UL http://medrxiv.org/content/early/2022/10/17/2022.09.06.22279660.abstract
AB Drug repurposing may provide a solution to the substantial challenges facing de novo drug development. Given that 66% of FDA-approved drugs in 2021 were supported by human genetic evidence, drug repurposing methods based on genome wide association studies (GWAS), such as drug gene-set analysis, may prove an efficient way to identify new treatments. However, to our knowledge, drug gene-set analysis has not been tested in non-psychiatric phenotypes, and previous implementations may have contained statistical biases when testing groups of drugs. Here, 1201 drugs were tested for association with hypercholesterolemia, type 2 diabetes, coronary artery disease, asthma, schizophrenia, bipolar disorder, Alzheimer’s disease, and Parkinson’s disease. We show that drug gene-set analysis can identify clinically relevant drugs (e.g., simvastatin for hypercholesterolemia [p = 2.82E-06]; mitiglinide for type 2 diabetes [p = 2.66E-07]) and drug groups (e.g., C10A for coronary artery disease [p = 2.31E-05]; insulin secretagogues for type 2 diabetes [p = 1.09E-11]) for non-psychiatric phenotypes. Additionally, we demonstrate that when the overlap of genes between drug-gene sets is considered we find no groups containing approved drugs for the psychiatric phenotypes tested. However, several drug groups were identified for psychiatric phenotypes that may contain possible repurposing candidates, such as ATC codes J02A (p = 2.99E-09) and N07B (p = 0.0001) for schizophrenia. Our results demonstrate that clinically relevant drugs and groups of drugs can be identified using drug gene-set analysis for a number of phenotypes. These findings have implications for quickly identifying novel treatments based on the genetic mechanisms underlying diseases.Competing Interest StatementNYB, EU, EvW, and DP have no conflicts of interest to declare. CdL was funded by F. Hoffman-La Roche AG.Funding StatementThis project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 964874. DP is supported by the Netherlands Organization for Scientific Research - Gravitation project 'BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology' (024.004.012), and DP and EU are funded by the European Research Council advanced grant 'From GWAS to Function' (ERC-2018-ADG 834057).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are publicly available and can be found using the links provided in the manuscript. https://github.com/nybell/drugsets https://clue.io/repurposing https://www.dgidb.org/ https://ctg.cncr.nl/software/summary_statistics https://atlas.ctglab.nl/ https://www.ebi.ac.uk/gwas/ http://diagram-consortium.org/downloads.html https://www.med.unc.edu/pgc/download-results/ https://ctg.cncr.nl/software/magma